Niki Stavroyianni

TL;DR: It is suggested that a particular antigen-binding site can be critical in determining the clinical features and outcome for at least some CLL patients.

TL;DR: In CLL, COVID-19 severity increases with age; antileukemic treatment (particularly BTK inhibitors) appears to exert a protective effect; age and comorbidities did not impact on mortality, alluding to a relevant role of CLL and immunodeficiency.

TL;DR: Novel insights are provided into the heterogeneous genetic landscape of CLL relapsing after FCR treatment and a novel mechanism underlying clinical aggressiveness involving a mutated ribosomal protein is highlighted, potentially representing an early genetic lesion in CLL pathobiology.

TL;DR: The existence of subsets that comprise given IGKV-J/IGLV-J domains associated with IGHV-D-J domain that display homologous CDR3 provides further evidence for the role of antigen in CLL pathogenesis.

TL;DR: A novel hierarchical model is proposed in which patients with high-CK exhibit the worst prognosis, whereas those with mutated CLL lacking CK or TP53abs, as well as CK with +12,+19, show the longest overall survival.